pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

ksq-therapeutics PRESS RELEASE ARCHIVE

Sep 6, 2023

KSQ Therapeutics and CTMC Announce Strategic Collaboration to Accelerate the Development of Novel Engineered Tumor Infiltrating Lymphocyte (eTIL) Therapies for the Treatment of Solid Tumors

Jul 13, 2023

KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer

May 17, 2023

KSQ Therapeutics and Takeda Expand Strategic Immuno-Oncology Collaboration to Identify and Validate Novel Tumor Targets

Jan 25, 2023

KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics Platform Technology

Dec 7, 2022

KSQ Therapeutics Announces First Patient Dosed in Combination Portion of the Ongoing Phase 1 Study of KSQ-4279, a First-In-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors

Sep 23, 2022

KSQ Therapeutics Announces Leadership and Board Additions

Mar 22, 2022

KSQ Therapeutics to Present Data at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Sep 22, 2021

KSQ Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

Sep 14, 2021

KSQ Therapeutics Announces First Patient Dosed in Phase 1 Study of KSQ-4279, a First-in-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors

May 13, 2021

KSQ Therapeutics Appoints Chris Heberlig as Chief Financial Officer

Mar 10, 2021

KSQ Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

Jan 13, 2021

KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies

Sep 24, 2020

KSQ Therapeutics to Present New Data from its USP1 Inhibitor Program at Upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Feb 9, 2020

KSQ Therapeutics Announces Discovery of Gene Targets with Potential Activity Superior to PD-1 for Development of Engineered Tumor Infiltrating Lymphocyte (eTIL™) Therapies for Solid Tumors

Dec 3, 2019

KSQ Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference and Provide Updates on Immuno-Oncology and Cell Therapy Programs

Nov 12, 2019

KSQ Therapeutics Enhances Board of Directors with Two Appointments

Oct 28, 2019

KSQ Therapeutics to Present First Data from its Proprietary CRISPRomics Discovery Engine

Oct 15, 2019

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

Oct 15, 2019

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

Apr 16, 2019

KSQ Therapeutics Announces Appointment of Beni B. Wolf, MD, PhD, as Chief Medical Officer

Apr 16, 2019

KSQ Therapeutics Announces Appointment of Douglas Pagán as Chief Financial Officer

Sep 28, 2018

KSQ Therapeutics Secures $80 Million Financing and Advances Broad Pipeline of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program for PD-1 Resistant Solid Tumors

Sep 25, 2018

KSQ Therapeutics Appoints Richard Moscicki, MD, to Board of Directors

Oct 2, 2017

KSQ Therapeutics Emerges with $76 Million in Financing to Pioneer High-Confidence Drug Development

Google Analytics Alternative